Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
After finishing at $18.20 in the prior trading day, NewAmsterdam Pharma Company NV (NASDAQ: NAMS) closed at $902.85K, up 1006111%. In other words, the price has increased by $1006111 from its previous closing price. On the day, 1.01 million shares were traded. NAMS stock price reached its highest trading level at $19.01 during the session, while it also had its lowest trading level at $17.76.
Ratios:
Our goal is to gain a better understanding of NAMS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 19.98 and its Current Ratio is at 19.98. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on June 17, 2025, initiated with a Buy rating and assigned the stock a target price of $42.
On June 10, 2025, Stifel started tracking the stock assigning a Buy rating and target price of $44.
On June 04, 2025, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $42.Cantor Fitzgerald initiated its Overweight rating on June 04, 2025, with a $42 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 16 ’25 when Kling Douglas F sold 100,000 shares for $19.29 per share. The transaction valued at 1,929,141 led to the insider holds 44,000 shares of the business.
Topper James N bought 8,584 shares of NAMS for $167,381 on Jun 16 ’25. The Director now owns 3,022,153 shares after completing the transaction at $19.50 per share. On Jun 16 ’25, another insider, NAP PoolCo B.V., who serves as the Affiliate of the company, bought 303,197 shares for $19.50 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NAMS now has a Market Capitalization of 2016387072 and an Enterprise Value of 1208293376. For the stock, the TTM Price-to-Sale (P/S) ratio is 42.77 while its Price-to-Book (P/B) ratio in mrq is 2.59. Its current Enterprise Value per Revenue stands at 25.632 whereas that against EBITDA is -6.373.
Stock Price History:
The Beta on a monthly basis for NAMS is -0.02, which has changed by -0.08507389 over the last 52 weeks, in comparison to a change of 0.09544468 over the same period for the S&P500. Over the past 52 weeks, NAMS has reached a high of $27.29, while it has fallen to a 52-week low of $14.06. The 50-Day Moving Average of the stock is -2.32%, while the 200-Day Moving Average is calculated to be -10.96%.
Shares Statistics:
The stock has traded on average 902.85K shares per day over the past 3-months and 1146150 shares per day over the last 10 days, according to various share statistics. A total of 112.17M shares are outstanding, with a floating share count of 62.21M. Insiders hold about 44.59% of the company’s shares, while institutions hold 57.42% stake in the company. Shares short for NAMS as of 1748563200 were 6558666 with a Short Ratio of 7.26, compared to 1745971200 on 5422008. Therefore, it implies a Short% of Shares Outstanding of 6558666 and a Short% of Float of 6.9699995.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
